CDMOs invest in European API capabilities to balance changing demand and supply chain risks, says GlobalData
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Order development and manufacturing companies (CDMOs) are increasing their investment in pharmaceutical active ingredients (APIs) in Europe. A number of recent transactions show how companies are expanding their infrastructure in the region to promote the development and supply of newer, more...
CDMOs invest in European API capabilities to balance changing demand and supply chain risks, says GlobalData
Contract development and manufacturing organizations (CDMOs) are ramping up their active pharmaceutical ingredient (API) investments in Europe. A series of recent deals shows how companies are strengthening their infrastructure in the region, as they position themselves to develop and supply newer, more complex medicines, says GlobalData, a leading intelligence and productivity platform. GlobalData’s monthly Bio/Pharmaceutical Outsourcing report…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
